Laurus Labs Ltd (Pharma - API & CRAMS) — fundamental analysis, earnings data, and key metrics. PE: 64.6. ROE: 7.5%. This stock is not currently in the Nifty 500 momentum outperformers list.
Based on Q3 FY26 earnings • Updated Feb 22, 2026
What: Vizag facility will boost Bio division revenue from current ₹43 cr quarterly run rate
Impact: +₹150 Cr revenue
“The Bio division reported Q3 sales of ₹43 crore, with plans for a Phase-1 capacity of over 400 kiloliters for the commercial-scale fermentation facility at Vizag to be operational by the end of 2026”
What: Capacity expansion to drive CDMO growth beyond current 50% 9M performance
Impact: +₹300 Cr revenue
“Discussions during the Q&A included CAPEX plans for FY27 (estimated to be over ₹1,000 crore), investments in peptides and ADCs”
What: 37% growth in generics driven by recently launched products in developed markets
Impact: +₹400 Cr revenue
“The generics division reported revenues of ₹1,327 crore for Q3, a 37% growth, supported by higher ARV volumes and strong offtake of recently launched products in developed markets”
Earnings deceleration risks from management commentary
Trigger: Q3 was softer due to timing of deliveries
Impact: -150 bps margin impact
Management view: Q3 was little softer because of timing of deliveries to our partners. But we expect if you look at Q4FY25 versus Q4FY26 we expect to grow
Monitor: Q4 CDMO revenue vs Q4 prior year
Trigger: Input cost increases or pricing pressure
Impact: -200 bps margin impact
Management view: Gross margins has expanded further from the previous quarters and maintained around 60%
Monitor: Gross margin trend in next 2 quarters
Key quotes from recent conference calls
“Oral solid facility expansion is progressing well, with a significant part of the plant capacity becoming operational during the quarter — Management”
“Gross margins has expanded further from the previous quarters and maintained around 60%. And EBITDA margins expanded to little over 27% — Management”
“Our cumulative nine month performance has been very healthy clocking more than 50% growth. This has been supported by strong recurring business from our existing long term customer relationships — Management”
“We expect if you look at Q4FY25 versus Q4FY26 we expect to grow — Management”
Forward-looking targets from management for FY27
Capex Plan
₹1000 Cr
Key Milestones
• 400KL fermentation facility operational by end-2026
• Peptide/ADC capacity expansion in FY27
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Feb 22, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Laurus Labs Ltd's latest quarterly results (Dec 2025) show
Laurus Labs Ltd's current PE ratio is 64.6x.
Laurus Labs Ltd's price-to-book ratio is 11.3x.
Laurus Labs Ltd's fundamental strength based on key financial ratios
Laurus Labs Ltd has a debt-to-equity ratio of N/A.
Laurus Labs Ltd's return ratios over recent years
Laurus Labs Ltd's operating cash flow is positive (FY2025).
Laurus Labs Ltd's current dividend yield is 0.12%.
Laurus Labs Ltd's shareholding pattern (Dec 2025)
Laurus Labs Ltd's promoter holding has decreased recently.
Laurus Labs Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
Laurus Labs Ltd has 3 key growth catalysts identified from recent earnings analysis
Laurus Labs Ltd has 2 key risks worth monitoring
In Q3 FY26, Laurus Labs Ltd's management highlighted
Laurus Labs Ltd's management has provided the following forward guidance for FY27
Based on quantitative research signals, here is why Laurus Labs Ltd may be worth studying
Laurus Labs Ltd investment thesis summary:
Laurus Labs Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
